Cystic Fibrosis organisations in Australia provide support and services to people with Cystic Fibrosis (CF) and their carers and families. This is complemented by a commitment to research and a quality improvement program focussing on improved clinical care for people with CF.
Every four days a baby is born in Australia with cystic fibrosis (CF) and more than one million Australians are carriers of cystic fibrosis. Cystic Fibrosis Australia (CFA) is committed to improving clinical practice and patient outcomes through its quality improvement programmes and research with the aim of extending life expectancy from 37 to 50 years by 2025.
Cystic Fibrosis is a recessive genetic condition. It primarily affects the lungs and digestive system because of a malfunction in the exocrine system, responsible for producing saliva, sweat, tears and mucus.
In addition to working for a cure, Cystic Fibrosis Australia also provides support and advocacy to improve the lives of people with cystic fibrosis. Get involved by raising awareness about CF, participating in a fundraising event or volunteering.
Cystic Fibrosis Australia has established a consistent approach to advocacy across Australia and is now a subject matter expert for government, industry and the media.
The Australian Cystic Fibrosis Research Trust (ACFRT) is managed by Cystic Fibrosis Australia (CFA). Since 1989 it has funded more than 300 projects valued at over $6,000,000.
Visit the media room to browse through number of resources including media representatives, press releases and reports.
Clinical trials are listed below.
Restore CFTR FunctionEnrolling
Location: Multiple care centres across the US (healthy volunteers) & Belfast (CF)
Phase I Study of PTI-808 and triple combination in healthy adults and then in adults with cystic fibrosis
, protocol number NCT03500263 PTI-808-01 Proteostasis
Parts 1 and 2 of this study will take place in healthy volunteers. Part 3 of this study is taking place in adults with cystic fibrosis at multiple care centers across the U.S. It will look at the safety, tolerability, and how the body processes the drug in multiple ascending doses of PTI-808 and PTI-808 together with PTI-428 and PTI-801.
18 years and older
Two copies of F508del
Number of Visits:
Length of Participation:
Restore CFTR FunctionCompleted with results
Phase 1 exploratory study on the effect of the drug QR-010 on nasal cells.
, protocol number NCT02564354 ProQR PQ-010-002
This study evaluated the effectiveness of the drug eluforsen (when sprayed in the nose) to improve nasal cell chloride transport. This study was for people with CF who have at least one copy of the F508del CFTR mutation.
18 Years and Older
Two copies F508del or One Copy F508del
40% or greater
SN06: Phase 2 study of N91115 in adults with CF who are currently taking lumacaftor/ivacaftor.
, protocol number NCT02589236 NIVALIS N91115-2CF1-05
This study evaluated the safety and effectiveness of the CFTR modulator drug N91115 (cavosonstat). This study was for adults with cystic fibrosis who have two copies of F508del CFTR mutation and were also taking lumacaftor/ivacaftor (Orkambi®).
Two copies F508del
40 to 85%
Restore CFTR FunctionEnrolling
SN07: Phase 2 study of N91115 in adults with CF who are currently taking ivacaftor
, protocol number Nivalis N91115-2CF-06
This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the oral drug N91115 and will use a placebo control.
One Copy F508del or No Copies F508del
40 to 90%
SNO1: Study of N6022 in people with cystic fibrosis
, protocol number Nivalis N30 N6022-1CF1-04
This study tested the safety, tolerability of N6022 and its effects on CFTR biomarkers in people with CF.
Nutritional-GICompleted with results
Study of in-line digestive enzyme cartridge (Relizorb) in people with CF who are currently receiving enterel tube feedings
, protocol number Alcresta 0000497
This study took place at multiple care centres across the US. It looked at the safety and effectiveness of Relizorb, a new tube feeding in-line digestive enzyme cartridge. This cartridge is used with tube feedings to deliver digestive enzymes.
4 Years to 82 Years
No Mutation Requirement
Less than 100%
Anti-InfectiveCompleted with results
Arikace for Nontuberculous Mycobacteria (NTM)
, protocol number Insmed 112
The purpose of this study was to determine whether Arikace is effective in treating recalcitrant nontuberculous mycobacterial lung disease. The safety and tolerability of Arikace in this patient population was also assessed.
12 Years to 75 Years
No FEV1 Limit
SNO4: Study of N91115 in people with cystic fibrosis ages 18 and older with two copies of F508del-CFTR mutation.
, protocol number Nivalis N91115-2CF-03
This study is taking place at multiple care centers across the U.S. It will look at the safety of the drug N91115 as well as how the body processes the drug, in people with CF.
Restore CFTR FunctionClosed to enrollment
Phase 2 study of riociguat in adults with CF
, protocol number Bayer 63-2521/17020
This study is taking place at multiple care centers across the U.S. It will look at the safety, tolerability and effectiveness of the oral drug riociguat and will use a placebo control.
60 to 90%
ASSURE: Study of Relizorb in people with CF who receive enteral tube feeding
, protocol number Alcresta 0000498
This open label study is taking place at multiple care centres across the US. It will look at the safety, tolerability and effectiveness of Relizorb, a new digestive enzyme cartridge for people using enteral tube feedings.
4 Years and Older